Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: One-year outcomes

American Journal of Transplantation

Volumn 10, Issue 2, 2010, Pages 382-388

  Teuteberg, J J ^a   Shullo, M A ^a   Zomak, R ^a   Toyoda, Y ^a   McNamara, D M ^a   Bermudez, C ^a   Kormos, R L ^a   McCurry, K R ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Alemtuzumab; Cardiac transplant; Rejection; Survival

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; CREATININE; CYCLOSPORIN; DIPHENHYDRAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; TACROLIMUS; VALGANCICLOVIR;

ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CONTROL GROUP; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOWER INTENSITY MAINTENANCE THERAPY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; VASCULAR DISEASE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CALCINEURIN; CYCLOPHOSPHAMIDE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; RETROSPECTIVE STUDIES; STEROIDS; TACROLIMUS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 75149189508     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02856.x     Document Type: Article

References (35)

1. Taylor DO, Edwards LB, Aurora P et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fifth official adult heart transplant report-2008. J Heart Lung Transplant 2008 27 : 943 956.
2. Mulligan MS, Shearon TH, Weill D, Pagani FD, Moore J, Murray S. Heart and lung transplantation in the United States, 1997-2006. Am J Transplant 2008 8 (4 Pt 2 977 987.
3. Radermacher J, Meiners M, Bramlage C et al. Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506. Transpl Int 1998 11 : 3 10.
4. Starling RC, Cody RJ. Cardiac transplant hypertension. Am J Cardiol 1990 65 : 106 111.
5. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: A systematic review of the literature. Diabetes Care 2002 25 : 583 592.
6. Akhlaghi F, Jackson CH, Parameshwar J, Sharples LD, Trull AK. Risk factors for the development and progression of dyslipidemia after heart transplantation. Transplantation 2002 73 : 1258 1264.
7. Ballantyne CM, Radovancevic B, Farmer JA et al. Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol 1992 19 : 1315 1321.
8. Zietse R, Balk AH, vd Dorpel MA, Meeter K, Bos E, Weimar W. Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol 1994 14 : 1 5.
9. Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990 35 : 118 127.
10. Ciancio G, Burke GW, Gaynor JJ et al. The use of Campath-1H as induction therapy in renal transplantation: Preliminary results. Transplantation 2004 78 : 426 433.
11. McCurry KR, Iacono A, Zeevi A et al. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 2005 130 : 528 537.
12. Knechtle SJ, Fernandez LA, Pirsch JD et al. Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery 2004 136 : 754 760.
13. Ortiz J, Palma-Vargas J, Wright F et al. Campath induction for kidney transplantation: Report of 297 cases. Transplantation 2008 85 : 1550 1556.
14. Barth RN, Janus CA, Lillesand CA et al. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int 2006 19 : 885 892.
15. Tan HP, Kaczorowski DJ, Basu A et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006 6 : 2409 2417. (Pubitemid 44359428)
16. Margreiter R, Klempnauer J, Neuhaus P, Muehlbacher F, Boesmueller C, Calne RY. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: Results of a prospective randomized trial. Am J Transplant 2008 8 : 1480 1485.
17. Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008 22 : 200 210.
18. Farney A, Sundberg A, Moore P et al. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. Clin Transplant 2008 22 : 41 49.
19. Magliocca JF, Odorico JS, Pirsch JD et al. A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation. Am J Transplant 2008 8 : 1702 1710.
20. Kaufman DB, Leventhal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results. Am J Transplant 2006 6 : 331 339.
21. Thai NL, Khan A, Tom K et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. Transplantation 2006 82 : 1621 1624.
22. Muthusamy AS, Vaidya AC, Sinha S, Roy D, Elker DE, Friend PJ. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. Am J Transplant 2008 8 : 2126 2131.
23. Marcos A, Eghtesad B, Fung JJ et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: With particular reference to hepatitis C virus. Transplantation 2004 78 : 966 971.
24. Tryphonopoulos P, Madariaga JR, Kato T et al. The impact of Campath 1H induction in adult liver allotransplantation. Transplant Proc 2005 37 : 1203 1204.
25. Lauro A, Amaduzzi A, Dazzi A et al. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period. Dig Liver Dis 2007 39 : 253 256.
26. Nishida S, Levi DM, Moon JI et al. Intestinal transplantation with alemtuzumab (Campath-1H) induction for adult patients. Transplant Proc 2006 38 : 1747 1749.
27. Agarwal A, Shen LY, Kirk AD. The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation. Transpl Immunol 2008 20 : 6 11.
28. Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int 2006 19 : 705 714.
29. Das B, Shoemaker L, Recto M, Austin E, Dowling R. Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: Successful outcome and rationale for its use. J Heart Lung Transplant 2008 27 : 242 244.
30. Pham SM, Jimenez J, Bednar BM et al. Campath 1-H in clinical heart transplantation. J Heart Lung Transplant 2006 25 (2S S126.
31. Rajab A, Pelletier RP, Henry ML, Ferguson RM. Excellent clinical outcomes in primary kidney transplant recipients treated with steroid-free maintenance immunosuppression. Clin Transplant 2006 20 : 537 546.
32. Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE Jr. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003 75 : 1396 1399.
33. Cantarovich D, Karam G, Hourmant M et al. Steroid avoidance versus steroid withdrawal after simultaneous pancreas-kidney transplantation. Am J Transplant 2005 5 : 1332 1338.
34. Yamani MH, Taylor DO, Czerr J et al. Thymoglobulin induction and steroid avoidance in cardiac transplantation: Results of a prospective, randomized, controlled study. Clin Transplant 2008 22 : 76 81.
35. Knechtle SJ, Pirsch JD, H Fechner J Jr. et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003 3 : 722 730.